CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma

Cancer Science

Volumn 104, Issue 8, 2013, Pages 989-995

  Okazaki, Yasumasa ^a   Nagai, Hirotaka ^a   Chew, Shan H ^a   Li, Jiang ^a   Funahashi, Satomi ^a   Tsujimura, Tohru ^b   Toyokuni, Shinya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CHRYSOTILE; CROCIDOLITE; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM; NONHUMAN; PERITONEUM MESOTHELIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 84881113677     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12185     Document Type: Article

References (32)

1. Gemba K, Fujimoto N, Kato K et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci 2012; 103: 483-90.
2. Robinson B, Lake R. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.
3. Robinson B, Musk A, Lake R. Malignant mesothelioma. Lancet 2005; 366: 397-408.
4. Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J Med Sci 2009; 71: 1-10.
5. Nagai H, Toyokuni S. Biopersistent fiber-induced inflammation and carcinogenesis: lessons learned from asbestos toward safety of fibrous nanomaterials. Arch Biochem Biophys 2010; 502: 1-7.
6. Hodgson J, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000; 44: 565-601.
7. IARC, WHO. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens; Part C: Arsenic, Metals, Fibres, and Dusts. Lyon, France, 2012; 219-309.
8. Husain AN, Colby TV, Ordonez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-31.
9. Lagana SM, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med 2012; 136: 804-9.
10. Bidlingmaier S, He J, Wang Y et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009; 69: 1570-7.
11. Sato A, Torii I, Okamura Y et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 2010; 23: 1458-66.
12. Ouhtit A, Gaur RL, Abd Elmageed ZY et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 2009; 1795: 130-6.
13. Zeng Q, Li W, Lu D et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 2012; 109: 1127-32.
14. Vikesaa J, Hansen TV, Jonson L et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006; 25: 1456-68.
15. Kapoor S. IMP3: a new and important biomarker of systemic malignancies. Clin Cancer Res 2008; 14: 5640; author reply 5640-1.
16. Lu D, Yang X, Jiang NY et al. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 2011; 35: 1638-45.
17. Shi M, Fraire AE, Chu P et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011; 35: 878-82.
18. Jiang L, Akatsuka S, Nagai H et al. Iron overload signature in chrysotile-induced malignant mesothelioma. J Pathol 2012; 228: 366-77.
19. Usami N, Fukui T, Kondo M et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 387-94.
20. Jiang L, Yamashita Y, Toyokuni S. A novel method for efficient collection of normal mesothelial cells in vivo. J Clin Biochem Nutr 2010; 46: 265-8.
21. Toyokuni S, Kawaguchi W, Akatsuka S, Hiroyasu M, Hiai H. Intermittent microwave irradiation facilitates antigen-antibody reaction in Western blot analysis. Pathol Int 2003; 53: 259-61.
22. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002; 118: 408-17.
23. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
24. Middleton J, Americh L, Gayon R et al. A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. J Pathol 2005; 206: 260-8.
25. Jaramillo-Ferrada PA, Wolvetang EJ, Cooper-White JJ. Differential mesengenic potential and expression of stem cell-fate modulators in mesenchymal stromal cells from human-term placenta and bone marrow. J Cell Physiol 2011; 227: 3234-42.
26. Pachon-Pena G, Yu G, Tucker A et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol 2011; 226: 843-51.
27. Donaldson K, Murphy FA, Duffin R, Poland CA. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010; 7: 5.
28. Takakura N. Formation and regulation of the cancer stem cell niche. Cancer Sci 2012; 103: 1177-81.
29. Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer 2006; 51: 53-9.
30. Saini SS, Klein MA. Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides. Anticancer Res 2011; 31: 3683-90.
31. Taheri ZM, Mehrafza M, Mohammadi F, Khoddami M, Bahadori M, Masjedi MR. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med 2008; 132: 694-7.
32. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.